^
Association details:
| Biomarker: | CTNNA1 deletion |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Role of alpha catenin in ovarian cancer cell line sensitivity to platinum-based chemotherapy and PARP inhibitors
Published date:
03/29/2020
Excerpt:
CRISPR/Cas9-mediated gene editing of CTNNA1 in SKOV3 and OVCAR3 cells resulted in a complete knockout of CTNNA1 expression in each cell line. When treated with carboplatin, both SKOV3 and OVCAR3 knockout cell lines were less sensitive to the drug than the parental lines. However, both knockout cell lines were more sensitive to treatment with olaparib compared to parental cell lines.
Secondary therapy:
carboplatin
